Consolidation in the pharmaceutical industry – an outlook for 2019

18 March 2019
michael_jewell_cavendish_big

An Expert View looking at the key factors that will drive deal activity over the next year from Michael Jewell, partner, head of healthcare & life sciences at Cavendish Corporate Finance.

Last year was an extraordinary period for consolidation in the pharmaceutical industry, with mergers and acquisitions (M&A) deals globally reaching $265 billion, a more than 25% surge on 2017.

As big pharma looks to increase pipelines of innovative and orphan drugs, particularly in the biopharma sub-sector, mega deals dominated the scene.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical